Document is current

Article History

Received: 17 December 2023

Accepted: 24 June 2024

First Online: 15 July 2024

Declarations

:

: The institutional review board of Aichi Cancer Center Hospital approved this protocol on June 9, 2023 (approval number: 2023-0-070). In this retrospective study, the need for informed consent was considered unnecessary according to the “Ethical Guidelines for Medical and Health Research Involving Human Subjects.” The summary of this research protocol was posted on the website of Aichi Cancer Center Hospital, and the participants were provided with the opportunity to opt-out.

: Not applicable.

: T.Y. received personal fees from Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Taiho Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, Bristol-Meyers Squibb and Boehringer Ingelheim. J.S. received personal fees from Chugai Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, MSD and AstraZeneca. R.M. received personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Chugai Pharmaceutical, Pfizer, Taiho Pharmaceutical, Ono Pharmaceutical, and MSD. Y.F. received grants from Chugai Pharmaceutical and personal fees from AstraZeneca, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Yakult, and Otsuka Pharmaceutical. All remaining authors declare no conflicts of interest.